BMY: Bristol-Myers Squibb Company - Summary | Jitta

Bristol-Myers Squibb Company

NYSE:BMY

Price
$57.89
Loss Chance
43.5%
5.22JITTA SCORE
75.66%Under Jitta Line
Jitta Ranking
94 / 1,157
1,095 / 5,055
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (35)
Recent Business Performance (18)
Financial Strength (57)
Return to Shareholders (84)
Competitive Advantage (54)
Jitta Signs
Interest Coverage RatioGood
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2020
Operating MarginInconsistent
Recent Business PerformanceEarning decline 2.72% in the last year
Key Stats
Jitta Score
Jitta Line
5.22
75.66%
1.97
168.71%
2.00
167.67%
Pharmaceuticals
2.62
91.88%
6.63
35.39%
4.26
83.22%
COMPANY DESCRIPTION
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.